RBC cut its target by 5%, from $20 to $19, but kept its Outperform rating and favorable view of the clinical-stage pipeline. Its speculative risk label remains, so the update gives no clear reason to change DSGN's outlook.
The lower target points to a less favorable view of the shares. Yet RBC still favors the clinical-stage pipeline and kept its Outperform rating. This is an analyst opinion, not new trial news, so the signals do not point clearly in one direction.
Follow Design Therapeutics (DSGN) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for DSGN